In 2021, the Global Artificial Ventilation and Anaesthesia Masks market were estimated to be worth around US$ 2.3 billion. With the increasing expenditure incurred on Artificial Ventilation and Anaesthesia Masks worldwide recently, the market is expected to reach a worth of about US$ 3.9 billion by the end of 2032, with a projected CAGR of 5.0% from 2022 to 2032. From 2017 to 2021, the Artificial Ventilation and Anaesthesia Masks Market experienced a growth of 5.7%.
| Attributes | Details |
|---|---|
| Global Artificial Ventilation and Anaesthesia Masks Market Size (2021) | US$ 2.3 billion |
| Global Artificial Ventilation and Anaesthesia Masks Market Size (2022) | US$ 2.4 billion |
| Projected Market Value (2032) | US$ 3.9 billion |
| Global Market Growth Rate (2022 to 2032) | 5% CAGR |
| United States Growth Rate (2022 to 2032) | 4.8% CAGR |
| Key Companies Profiled |
|
More than 50% of patients admitted to an intensive care unit (ICU) receive a treatment involving Artificial Ventilation and Anaesthesia Masks. The rising geriatric population is one of the key factors boosting the artificial ventilation and anaesthesia masks market. In 2012, the United Nations projected the geriatric population to rise to over 2 billion by 2050. A rise in the geriatric population often increases chronic diseases such as sleep apnea devices, cancer, COPD, kidney failure, and coronary artery diseases. This boosts the demand for surgical procedures, and in turn, increases the artificial ventilation and anaesthesia masks.
The artificial ventilation and anaesthesia mask market is also boosted by the increasing number of COPD patients. The disease is likely to be the third leading cause of death globally as estimated by WHO. Around 12.7 million adults have been reported to have COPD in the USA alone. The growing need for long-term home care and emergency treatment for lung diseases in adults as well as children is expected to boost demand for artificial ventilation and anaesthesia masks in the near future.
The demand for Artificial Ventilators has increased due to the availability of both, invasive and non-invasive ventilators in the market. Similarly, anaesthesia masks are also available for different cases like full face masks, nasal masks, hybrid masks, oral masks, nasal pillows etc. However, the high cost of artificial ventilation in healthcare is expected to slow the growth of the market in certain developing nations.
Artificial Ventilation and Anaesthesia Masks are used most in operation rooms and account for 51.7% of the market share. From 2017 to 2021, the use of Artificial Ventilation and Anaesthesia Masks in operation rooms has increased with a CAGR of 5.5% and is expected to experience a CAGR of 4.8% in the next ten years, from 2022 to 2032. This is largely due to various policies implemented by governments worldwide to make public healthcare accessible to everyone. Every year, more than 340 million operations are performed worldwide, providing huge opportunities for the Artificial Ventilation and Anaesthesia Masks Market.
Recently, the demand for Artificial Ventilation and Anaesthesia Masks are increasing due to their increasing use in-home care. Especially during the pandemic, when most patients wanted to avoid hospitals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America holds the largest market for Artificial Ventilation and Anaesthesia Masks. From 2017 to 2021, the North American Artificial Ventilation and Anaesthesia Masks market experienced a CAGR of 5.3% and is projected to see a CAGR of 4.7% in the next ten years.
According to a study an American is expected to get seven operations done on average in his or her entire lifetime and the number of the USA patients who get any kind of complication from surgery is around 1.5 million thus, increasing the demand for Artificial Ventilation and Anaesthesia Masks.
Another key driving factor in the North American Artificial Ventilation and Anaesthesia Masks Market is the increasing rates of chronic diseases and surgeries in Canada. Approximately 31 out of 100,000 Canadians die from chronic respiratory diseases, as per 2020 reports. And around 2 million surgeries are performed in Canada every year. All these factors are driving the Artificial Ventilation and Anaesthesia Masks Market in North America.
The United States has the largest market for Artificial Ventilation and Anaesthesia Masks, which is projected to reach a valuation of US $ 1.4 billion by 2032. From 2017 to 2021, the market in the United States grew at a CAGR of 4.8%. Between 2022 and 2032, the United States is expected to be a market with a US$ 509.3 million absolute dollar opportunity.
In the United States, every year 5 million people are admitted to ICUs. The number of Americans that were affected by chronic sleep disorders as per a report published by the National Sleep Foundation in 2012. This is expected to increase the demand for Ventilation Equipment and Anaesthesia Masks in the next ten years as these patients are more likely to visit the emergency department and intensive care unit.
Another reason which is helping in boosting the United States Artificial Ventilation and Anaesthesia masks Market is the introduction of The Affordable Care Act by The United States as more patients are now encouraged to opt for surgical treatments.
China’s market is still in the budding stage. China’s Market is projected to reach a valuation of US $ 280.4 million by 2032. From 2017 to 2021, the market in China grew at a CAGR of 4.3%. Between 2022 and 2032, China is expected to be a market with a US $ 96.8 million absolute dollar opportunity. In 2020, critical care artificial ventilators and anaesthesia masks made up more than 70% of the overall artificial ventilators and anaesthesia masks market in China.
A key reason for the growth of the Artificial Ventilation and Anaesthesia Masks Market in China is the growing older population in the country. The older population in China is expected to reach 198 million by the year 2025, as per the United States Census Bureau. This provides ample opportunities for players in the Artificial Ventilation and Anaesthesia Masks Market. China also exported the most number of Artificial Ventilators and Anaesthesia Masks worldwide, during the pandemic. China exported 16,000 artificial ventilators and anaesthesia masks in just one month during the pandemic.
In 2021, the leading players in China’s Artificial Ventilation and Anaesthesia Masks were Getinge AB, Dragerwerk AG & Co KGaA, Nihon Kohden Corp and Hamilton Medical AG.
The Market for Artificial Ventilation and Anaesthesia Market in Japan is expected to experience a CAGR of 3.4% in the next ten years with an absolute dollar opportunity of US $ 64.8 million. By 2032, the Japanese market for Artificial Ventilation and Anaesthesia Market is expected to be worth US $ 226.1 million.
Principal Consultant
Artificial Ventilation and Anaesthesia Masks market is moderately competitive and has numerous players. Many key companies are now focusing on collaborating on new research and development activities.
The key companies operating in the Artificial Ventilation and Anaesthesia Masks Market are CareFusion Corporation, Air Liquide Healthcare, Koninklijke Philips N.V., Fisher and Paykel Healthcare, ResMed, Ambu A/S, Acutronic Medical Systems, GaleMed, HOFFRICHTER GmbH and Dragerwerk SA.
Some of the recent developments by the key providers of Artificial Ventilation and Anaesthesia Masks are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global Artificial Ventilation and Anaesthesia Masks Market were valued at US$ 2.3 billion in 2021.
Over the projected period, the Artificial Ventilation and Anaesthesia Masks Market are expected to increase at a rate of 5%, reaching a value of US$ 3.9 billion by 2032.
The involvement of technology in Artificial Ventilation and Anaesthesia Masks and the growing geriatric population has been adding significant revenues to the market.
The Artificial Ventilation and Anaesthesia Masks Market expanded at 5.7% from 2017 through 2021.
Artificial Ventilation and Anaesthesia Masks are used the most in Operation Rooms. Revenue through this category expanded at a CAGR of 5.5% from 2017 to 2021, and is projected to grow at a CAGR of 4.8% by 2032.
CareFusion Corporation, Air Liquide Healthcare, Koninklijke Philips N.V., ResMed, Ambu A/S, Acutronic Medical Systems, GaleMed, are some of the key players in the Artificial Ventilation and Anaesthesia Masks Industry.
The United States, The United Kingdom, China, Japan and South Korea are expected to drive the most Artificial Ventilation and Anaesthesia Masks.
The United States has the largest market for Artificial Ventilation and Anaesthesia Masks.
1. Executive Summary | Artificial Ventilation and Anaesthesia Masks Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ million) & Volume (Units) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ million) & Volume (Units) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Application, 2017 to 2021
5.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Application, 2022 to 2032
5.3.1. Operation Room
5.3.2. Intensive Care Value (US$ million) & Volume (Units)
5.3.3. Emergency Room
5.3.4. Dental
5.3.5. Home Care
5.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Risk of Procedure
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Risk of Procedure, 2017 to 2021
6.3. Current and Future Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Risk of Procedure, 2022 to 2032
6.3.1. High-Risk Patients
6.3.2. Moderate-Risk Patients
6.3.3. Standard Patients
6.4. Y-o-Y Growth Trend Analysis By Risk of Procedure, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Risk of Procedure, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ million) & Volume (Units) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ million) & Volume (Units) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. Middle East and Africa (MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Application
8.2.3. By Risk of Procedure
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Application
8.3.3. By Risk of Procedure
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Rest of Latin America
9.2.2. By Application
9.2.3. By Risk of Procedure
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Application
9.3.3. By Risk of Procedure
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. The United Kingdom
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Application
10.2.3. By Risk of Procedure
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Application
10.3.3. By Risk of Procedure
10.4. Key Takeaways
11. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Application
11.2.3. By Risk of Procedure
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Application
11.3.3. By Risk of Procedure
11.4. Key Takeaways
12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Application
12.2.3. By Risk of Procedure
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Application
12.3.3. By Risk of Procedure
12.4. Key Takeaways
13. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Application
13.2.3. By Risk of Procedure
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Application
13.3.3. By Risk of Procedure
13.4. Key Takeaways
14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
14.1. Historical Market Size Value (US$ million) & Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2021
14.2. Market Size Value (US$ million) & Volume (Units) Forecast By Market Taxonomy, 2022 to 2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By Application
14.2.3. By Risk of Procedure
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Application
14.3.3. By Risk of Procedure
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. The USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Application
15.1.2.2. By Risk of Procedure
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Application
15.2.2.2. By Risk of Procedure
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Application
15.3.2.2. By Risk of Procedure
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Application
15.4.2.2. By Risk of Procedure
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Application
15.5.2.2. By Risk of Procedure
15.6. Germany
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Application
15.6.2.2. By Risk of Procedure
15.7. Italy
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Application
15.7.2.2. By Risk of Procedure
15.8. France
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Application
15.8.2.2. By Risk of Procedure
15.9. The United Kingdom
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Application
15.9.2.2. By Risk of Procedure
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Application
15.10.2.2. By Risk of Procedure
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Application
15.11.2.2. By Risk of Procedure
15.12. BENELUX
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Application
15.12.2.2. By Risk of Procedure
15.13. China
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Application
15.13.2.2. By Risk of Procedure
15.14. Japan
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Application
15.14.2.2. By Risk of Procedure
15.15. South Korea
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Application
15.15.2.2. By Risk of Procedure
15.16. India
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Application
15.16.2.2. By Risk of Procedure
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Application
15.17.2.2. By Risk of Procedure
15.18. Malaysia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Application
15.18.2.2. By Risk of Procedure
15.19. Indonesia
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Application
15.19.2.2. By Risk of Procedure
15.20. Australia
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Application
15.20.2.2. By Risk of Procedure
15.21. New Zealand
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2021
15.21.2.1. By Application
15.21.2.2. By Risk of Procedure
15.22. GCC Countries
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2021
15.22.2.1. By Application
15.22.2.2. By Risk of Procedure
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Application
16.3.3. By Risk of Procedure
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. CareFusion Corporation
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Air Liquide Healthcare
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Koninklijke Philips N.V.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Fisher and Paykel Healthcare
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. ResMed
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Ambu A/S
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Hamilton Medical
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Acutronic Medical Systems
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. GaleMed
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. HOFFRICHTER GmbH
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy
17.1.11. Dragerwerk SA
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.11.5.2. Product Strategy
17.1.11.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Artificial Ventilation and Anaesthesia Masks Market
